Lewis and his colleagues tested an experimental drug with those properties, MK-077, in a randomized, double-blind, controlled
trial of 15 subjects. (MK-077 was originally developed as a nonsedating antianxiety drug.) They found some improvement on
several cognitive tests reflecting processes in the dorsolateral prefrontal cortex, which is known to be impaired in schizophrenia.